WO2004008137A3 - Methode de diagnostic et de traitement de tumeurs du sein resistant au traitement anti-estrogene - Google Patents

Methode de diagnostic et de traitement de tumeurs du sein resistant au traitement anti-estrogene Download PDF

Info

Publication number
WO2004008137A3
WO2004008137A3 PCT/EP2003/007449 EP0307449W WO2004008137A3 WO 2004008137 A3 WO2004008137 A3 WO 2004008137A3 EP 0307449 W EP0307449 W EP 0307449W WO 2004008137 A3 WO2004008137 A3 WO 2004008137A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiestrogen
protein
antiestrogen treatment
treatment
breast tumor
Prior art date
Application number
PCT/EP2003/007449
Other languages
English (en)
Other versions
WO2004008137A2 (fr
Inventor
Iduna Fichtner
Michael Becker
Perez Vladimir Besada
Serra Lila Castellanos
Original Assignee
Max Delbrueck Centrum
Ct For Genetic Engineering And
Iduna Fichtner
Michael Becker
Perez Vladimir Besada
Serra Lila Castellanos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10310198A external-priority patent/DE10310198A1/de
Application filed by Max Delbrueck Centrum, Ct For Genetic Engineering And, Iduna Fichtner, Michael Becker, Perez Vladimir Besada, Serra Lila Castellanos filed Critical Max Delbrueck Centrum
Priority to AU2003253050A priority Critical patent/AU2003253050A1/en
Publication of WO2004008137A2 publication Critical patent/WO2004008137A2/fr
Publication of WO2004008137A3 publication Critical patent/WO2004008137A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode de diagnostic et de traitement de tumeurs du sein résistant à un traitement anti-estrogène, au moyen de protéines cibles spécifiques et des acides nucléiques codant pour ces dernières. Ladite méthode est basée sur la détermination de l'expression différentielle de gènes cibles spécifiques sur les acides nucléiques et du niveau de protéines dans des cellules de tumeurs du sein résistant au traitement anti-estrogène. Ladite méthode trouve des application en médecine et dans l'industrie pharmaceutique. Ladite méthode se caractérise en ce que la concentration d'au moins une protéine cible spécifique est déterminée dans le tissu de la tumeur et est comparée à la valeur de référence standard de la ou des mêmes protéines dans le tissu de tumeur du sein sensible au traitement anti-estrogène. Une concentration de protéine dans l'échantillon examiné supérieure à la valeur de référence standard indique une résistance de la tumeur au traitement anti-estrogène, s'il s'agit d'une protéine exprimée à des niveaux supérieurs dans des cellules de tumeur du sein résistant au traitement anti-estrogène, par rapport aux cellules de tumeur du sein sensibles au traitement anti-estrogène ; ou une concentration de protéine dans l'échantillon examiné inférieure à la valeur de référence standard indique la résistance de la tumeur au traitement anti-estrogène, s'il s'agit d'une protéine exprimée à un niveau inférieur dans les cellules de tumeur du sein résistant au traitement anti-estrogène, par rapport aux cellules de tumeurs du sein sensibles au traitement anti-estrogène.
PCT/EP2003/007449 2002-07-12 2003-07-10 Methode de diagnostic et de traitement de tumeurs du sein resistant au traitement anti-estrogene WO2004008137A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003253050A AU2003253050A1 (en) 2002-07-12 2003-07-10 Diagnosis and therapy of breast tumours resistant to antiestrogen treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10231873.5 2002-07-12
DE10231873 2002-07-12
DE10310198A DE10310198A1 (de) 2002-07-12 2003-03-06 Verfahren zur Diagnose und Therapie von antiöstrogentherapieresistenten Brusttumoren
DE10310198.5 2003-03-06

Publications (2)

Publication Number Publication Date
WO2004008137A2 WO2004008137A2 (fr) 2004-01-22
WO2004008137A3 true WO2004008137A3 (fr) 2004-09-02

Family

ID=30116640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007449 WO2004008137A2 (fr) 2002-07-12 2003-07-10 Methode de diagnostic et de traitement de tumeurs du sein resistant au traitement anti-estrogene

Country Status (2)

Country Link
AU (1) AU2003253050A1 (fr)
WO (1) WO2004008137A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1761648A1 (fr) * 2004-06-18 2007-03-14 Roche Diagnostics GmbH Utilisation de la proteine pdx1 comme marqueur pour le cancer du sein
CN102346190A (zh) * 2011-01-24 2012-02-08 中国人民解放军第三军医大学 用于检测生物标本中的过氧化物还原酶ⅳ的双抗夹心elisa试剂盒及其方法与运用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001063292A2 (fr) * 2000-02-22 2001-08-30 Board Of Regents, The University Of Texas System Compositions et utilisations de het, un nouveau modulateur de l'action oestrogenique

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001063292A2 (fr) * 2000-02-22 2001-08-30 Board Of Regents, The University Of Texas System Compositions et utilisations de het, un nouveau modulateur de l'action oestrogenique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERGGREN MARGARETA I ET AL: "Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 392, no. 1, 1 August 2001 (2001-08-01), pages 103 - 109, XP002266115, ISSN: 0003-9861 *
HILSENBECK S G ET AL: "STATISTICAL ANALYSIS OF ARRAY EXPRESSION DATA AS APPLIED TO THE PROBLEM OF TAMOXIFEN RESISTANCE", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 91, no. 5, 26 January 1999 (1999-01-26), pages 453 - 459, XP009002755, ISSN: 0027-8874 *
KARIHTALA PEETER ET AL: "Peroxiredoxins in breast carcinoma.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES 15 AUG 2003, vol. 9, no. 9, 15 August 2003 (2003-08-15), pages 3418 - 3424, XP002266133, ISSN: 1078-0432 *
NOH DONG-YOUNG ET AL: "Overexpression of peroxiredoxin in human breast cancer", ANTICANCER RESEARCH, vol. 21, no. 3B, May 2001 (2001-05-01), pages 2085 - 2090, XP008026146, ISSN: 0250-7005 *
SEITH P ET AL: "Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression)", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 21, 23 January 2002 (2002-01-23), pages 836 - 843, XP002965930, ISSN: 0950-9232 *
SHOU J ET AL: "Onset of endocrine resistance in breast cancer is associated with increased actibe p38 MAPK", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 69, no. 3, October 2001 (2001-10-01), pages 254, XP002960169, ISSN: 0167-6806 *

Also Published As

Publication number Publication date
AU2003253050A8 (en) 2004-02-02
WO2004008137A2 (fr) 2004-01-22
AU2003253050A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
Dobashi et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas
Abasi et al. Bioelectrical impedance spectroscopy for monitoring mammalian cells and tissues under different frequency domains: A review
DE60327354D1 (de) Diagnostischer assay zur bestimmung einer zellvermittelten immunantwort
WO2005098046A3 (fr) Methodes de determination de biomarqueurs specifiques de cellules
ATE429495T1 (de) Nukleinsäuren für die apoptose von krebszellen
CN110004149A (zh) 一种程序性死亡受体-配体1的核酸适体及其应用
WO2002078526A3 (fr) Antigenes vis-a-vis du cancer du testicule
WO2001071357A3 (fr) Proteines, genes et leur utilisation pour diagnostiquer et traiter le cancer de la poitrine
Devaraj Salivary biomarkers-a review
WO2007071829A3 (fr) Méthodes et moyens relatifs à des maladies
WO2003031572A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation
WO2004008137A3 (fr) Methode de diagnostic et de traitement de tumeurs du sein resistant au traitement anti-estrogene
KR20210143866A (ko) Kdm5a 유전자 및 atrx 유전자의 용도
KR101720050B1 (ko) 폐암관련 돌연변이 증폭용 프라이머 세트, 및 상기 돌연변이에 상보적인 프로브를 포함하는, 폐암 진단용 키트
WO2004053075A3 (fr) Compositions, variants d'epissage et procedes relatifs a des genes et des proteines specifiques du sein
WO2005110460A3 (fr) Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1)
WO2003106648A3 (fr) Compositions et methodes associees a des genes et a des proteines specifiques du sein
WO2004013311A3 (fr) Compositions et methodes se rapportant a des genes et proteines specifiques de l'ovaire
CN105087794A (zh) 一种检测结核病的试剂盒
WO2007058992A3 (fr) Mutations et polymorphismes de hdac6
JP2020153742A (ja) 進行期非扁平上皮肺癌患者の化学療法反応性を評価するための情報を提供する方法
WO2003066877A3 (fr) Compositions et procedes se rapportant a des genes et proteines specifiques hepatiques
CN104593515A (zh) 检测pik3ca基因h点突变的pcr-rflp方法
Liang et al. 186P CIP2A modulates PKM2 dimer-tetramer transition through phosphorylation of serine 287 in non-small cell lung cancer
Walter 185P Clinicopathological characterization of NGS detected mutations in lung cancers: A single center experience

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP